Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Mol Histol. 2024 Dec;55(6):1315-1325. doi: 10.1007/s10735-024-10272-8. Epub 2024 Oct 9.
Diabetes mellitus represents a prominent global health concern, characterized by a rising prevalence rate. Type 2 Diabetes Mellitus (T2DM) is purported to be associated with an intricate interplay of genetic, environmental, and lifestyle factors. While some progress have been made in T2DM management, controlling associated complications remains a great challenge in medicine.
This study investigated a synthesized Imidazolyl Thiazolidinedione antidiabetic agent (PA9), focusing on serum parameters.
Streptozotocin-induced diabetic rats (n = 6) were subjected to orally treatment with PA9 (synthesized by Shakour et al. in an equal dose of a standard drug, 0.011 mmol/kg). The study conducted to measure some specific serum factors, including lipid profiles, liver and kidney enzymes, cardiac enzymes, and oxidative stress markers, both before and after treatment.
The study findings indicated that PA9 effectively ameliorates hyperlipidemia by significantly reducing total cholesterol and triglyceride levels in serum. Additionally, PA9 demonstrated hepatoprotective effects against TZD-induced injuries, as evidenced by decreased levels of alanine transaminase and, alkaline phosphatase. In addition, PA9 also exhibited a modulatory effect on a cardiac injury marker, creatine kinase MB. Moreover, PA9 demonstrated antioxidant properties by reducing oxidative stress markers and enhancing the activities of catalase, thiol, and superoxide dismutase.
The synthesized TZD compound (PA9) stands out as a highly promising agent for the management of diabetes. Its significant antihyperlipidemic effects, preventive influences on organ injuries, and demonstrated efficacy in reducing oxidative stress marker (SOD) make it therapeutic agent in diabetes management. This study lays the groundwork for innovative strategies in diabetes management.
糖尿病是一个突出的全球健康问题，其患病率呈上升趋势。2 型糖尿病（T2DM）被认为与遗传、环境和生活方式因素的复杂相互作用有关。虽然在 T2DM 管理方面取得了一些进展，但控制相关并发症仍然是医学上的一大挑战。
本研究调查了一种合成的咪唑并噻唑烷二酮类抗糖尿病药物（PA9），重点研究其对血清参数的影响。
链脲佐菌素诱导的糖尿病大鼠（n=6）给予 PA9（由 Shakour 等人以与标准药物相等的剂量（0.011mmol/kg）合成）口服治疗。该研究旨在测量一些特定的血清因子，包括血脂谱、肝肾功能酶、心肌酶和氧化应激标志物，分别在治疗前后进行测量。
研究结果表明，PA9 可有效改善血脂异常，显著降低血清总胆固醇和甘油三酯水平。此外，PA9 对 TZD 诱导的损伤具有肝保护作用，表现为丙氨酸氨基转移酶和碱性磷酸酶水平降低。此外，PA9 还对心肌损伤标志物肌酸激酶 MB 具有调节作用。此外，PA9 通过降低氧化应激标志物和增强过氧化氢酶、巯基和超氧化物歧化酶的活性来表现出抗氧化特性。
合成的 TZD 化合物（PA9）是一种极具前景的糖尿病治疗药物。它具有显著的抗高血脂作用、对器官损伤的预防作用以及降低氧化应激标志物（SOD）的功效，使其成为糖尿病管理的治疗药物。本研究为糖尿病管理的创新策略奠定了基础。
